Bundibugyo Virus Disease Outbreak Alert
The Centers for Disease Control and Prevention (CDC) has issued a Level 2 travel health alert regarding outbreaks of Bundibugyo virus disease (BVD) in the Democratic Republic of the Congo (DRC) and Uganda, as of July 15, 2026.
Outbreak Status
Bundibugyo virus is one of six known species of Ebola virus and causes a hemorrhagic fever with significant morbidity and mortality. Current outbreaks have been confirmed in both the DRC and Uganda, with the DRC experiencing disease activity in specific provinces.
CDC Recommendations
The CDC recommends that travelers to affected areas:
- Practice enhanced precautions when traveling to Uganda or affected provinces in the DRC
- Avoid contact with blood and body fluids of infected persons
- Avoid contact with surfaces and materials contaminated by these fluids
- Avoid funeral rites that involve handling the deceased
- Avoid contact with fruit bats (possible reservoir species) and primates
- Practice frequent hand hygiene and use personal protective equipment when appropriate
- Seek immediate medical attention if symptoms develop during or after travel
Symptoms and Monitoring
Ebola virus disease symptoms typically appear 2-21 days after exposure and include fever, headache, muscle pain, weakness, fatigue, rash, vomiting, diarrhea, impaired kidney and liver function, and in some cases, internal and external bleeding. Travelers should monitor their health closely upon return home.
Medical Preparedness
Travelers to endemic areas should:
- Consult with travel medicine specialists before departure
- Ensure comprehensive travel health insurance including evacuation coverage
- Know the location of reliable medical facilities in destination areas
- Maintain awareness of symptoms requiring immediate medical evaluation
Pharmacist's Note: While no specific antiviral medications are FDA-approved for Ebola treatment, supportive care remains the cornerstone of management. Travelers should be aware that standard medications may not be reliably available in outbreak zones. Maintain an adequate supply of personal medications, first-aid supplies, and consider carrying medical records. No post-exposure prophylaxis medication is currently approved for public use, making prevention through strict infection control the primary strategy. Consult a travel medicine pharmacist to review your medication regimen for potential drug interactions with antimalarials or other common travel medications, as these may be concurrently recommended depending on destination.
Additional Resources
For current information, visit the CDC travel health notices page or consult with a travel medicine specialist before planning travel to affected regions.